BerGenBio AS, a Bergen, Norway-based oncology biopharma company, has completed an $8.8m Series A financing round.
The funding will be used primarily to take lead compound BGB324 – an inhibitor of AXL kinase – into clinical trials and to develop a companion diagnostic.
Led by CEO Richard Godfrey, BerGenBio is an oncology-based biopharmaceutical company focused on pursuing novel therapeutic treatments for cancer and supporting the screening and identification of a wide array of potential targets in collaboration with other pharmaceutical companies. The company has a proprietary platform technology called CellSelect™, which uses information from RNAi screening studies to identify novel drug targets involved in disease. It has a deep understanding of cancer biology and in particular the tumor micro-environment, EMT and mechanisms of drug resistance.